Large Outflow of Money Witnessed in Pacira Pharmaceuticals

Pacira Pharmaceuticals (PCRX) : Net money flow in Pacira Pharmaceuticals (PCRX) was negative ($2.97 million) and the inflow of money on uptick was $2.39 million, whereas, the outflow of money on downticks amounted to $5.36 million on Friday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.45. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $3.04 million. The money flow in block trades was negative ($3.04). Pacira Pharmaceuticals (PCRX) gained $0.5 cent during the day and reached $38.14, a gain of 1.33% over the previous day.


Pacira Pharmaceuticals (PCRX) : The most positive equity analysts on Pacira Pharmaceuticals (PCRX) expects the shares to touch $105, whereas, the least positive believes that the stock will trade at $59 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $77.13 with an expected fluctuation of $14.04 from the mean.

Pacira Pharmaceuticals (NASDAQ:PCRX): stock turned positive on Friday. Though the stock opened at $37.65, the bulls momentum made the stock top out at $38.41 level for the day. The stock recorded a low of $36.71 and closed the trading day at $38.35, in the green by 1.89%. The total traded volume for the day was 476,243. The stock had closed at $37.64 in the previous days trading.

In a related news, Brege Laura, director of Pacira Pharmaceuticals, Inc., unloaded 1,000 shares at an average price of $46.95 on June 6, 2016. The total amount of the transaction was worth $46,950, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.